EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Furong Li, Yanping Lin, Rong Li, Xin Shen, Mengying Xiang, Guangrui Xiong, Ke Zhang, Tingrong Xia, Jiangyan Guo, Zhonghui Miao, Yedan Liao, Xuan Zhang und 1 weitere

Frontiers in Pharmacology · 20.10.2023 · 14

DOI: 10.3389/fphar.2023.1165666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.10.2023. Verfasst von Furong Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) represents 10% of all cancer types, making it the third leading cause of cancer-related deaths globally. Metastasis is the primary factor causing mortality in CRC patients. Approximately 22% of CRC-related deaths have metastasis present at diagnosis, with approximately 70% of these cases recurring. Recently, with the application of novel targeted drugs, targeted therapy has become the first-line option for individualized and comprehensive treatment of CRC. The management of these patients remains a significant medical challenge. The most prevalent targeted therapies for CRC in clinical practice focus on anti-vascular endothelial growth factor and its receptor, epidermal growth factor receptor (EGFR), and multi-target kinase inhibitors. In the wake of advancements in precision diagnosis and widespread adoption of second-generation sequencing (NGS) technology, rare targets such as BRAF V600E mutation, KRAS mutation, HER2 overexpression/amplification, and MSI-H/dMMR in metastatic colorectal cancer (mCRC) are increasingly being discovered. Simultaneously, new therapeutic drugs targeting these mutations are being actively investigated. This article reviews the progress in clinical research for developing targeted therapeutics for CRC, in light of advances in precision medicine and discovery of new molecular target drugs.

Schlagwörter

Stichwörter der Autor:innen

Her-2RASVEGFcolorectal cancerepidermal growth factor receptormolecular targeted therapy

Autor:innen und Institutionen

  • Department of Colorectal Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
  • Department of Gastroenterology and Internal Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
  • Department of Pathology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.

Zitieren

APA

Li, F., Lin, Y., Li, R., Shen, X., Xiang, M., Xiong, G., Zhang, K., Xia, T., Guo, J., Miao, Z., Liao, Y., Zhang, X., & Xie, L. (2023). Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1165666

Vancouver

Li F, Lin Y, Li R, Shen X, Xiang M, Xiong G, et al. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1165666

BibTeX
@article{Li2023,
  author = {Li, Furong and Lin, Yanping and Li, Rong and Shen, Xin and Xiang, Mengying and Xiong, Guangrui and Zhang, Ke and Xia, Tingrong and Guo, Jiangyan and Miao, Zhonghui and Liao, Yedan and Zhang, Xuan and Xie, Lin},
  title = {Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1165666}
}
Kostenlos starten →